Response by Gibson and Fox to Letter Regarding Article, "Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy"

Affiliations

Comment

C Michael Gibson et al. Circulation. 2017.

. 2017 Jul 4;136(1):117.

doi: 10.1161/CIRCULATIONAHA.117.028416.

¹ From Harvard Medical School, Boston, MA (C.M.G.); and University of Edinburgh, Scotland (K.F.).

No abstract available

Comment on

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GY, Cohen M, Peterson ED, Fox KA. Gibson CM, et al. Circulation. 2017 Jan 24;135(4):323-333. doi: 10.1161/CIRCULATIONAHA.116.025783. Epub 2016 Nov 14. Circulation. 2017. PMID: 27881555 Free PMC article. Clinical Trial.
Letter by Cerit Regarding Article, "Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy".
Cerit L. Cerit L. Circulation. 2017 Jul 4;136(1):115-116. doi: 10.1161/CIRCULATIONAHA.117.027683. Circulation. 2017. PMID: 28674097 No abstract available.